TAU Breakthrough Offers New Hope to Help People With Paralysis Walk Again

Written on |

Researchers successfully engineer world’s first 3D human spinal cord tissue transplant.

Paralysis from spinal injury has long remained untreatable. Could scientific developments get people affected on their feet again sooner than imagined? In a worldwide first, Tel Aviv University researchers have engineered 3D human spinal cord tissues and implanted them in a lab model with long-term chronic paralysis, demonstrating high rates of success in restoring walking abilities. Now, the researchers are preparing for the next stage of the study, clinical trials in human patients. They hope that within a few years the engineered tissues will be implanted in paralyzed individuals enabling them to stand up and walk again.

How to Reverse Spinal Injury?

“Our technology is based on taking a small biopsy of belly fat tissue from the patient,” explains Prof. Tal Dvir who’s research team led the study. “This tissue, like all tissues in our body, consists of cells together with an extracellular matrix comprising substances like collagens and sugars. After separating the cells from the extracellular matrix we used genetic engineering to reprogram the cells, reverting them to a state that resembles embryonic stem cells – namely cells capable of becoming any type of cell in the body.”

 

Petri dish with tissue samples (Photo: Sagol Center for Regenerative Biotechnology)

From the extracellular matrix the researchers produced a personalized hydrogel, that would evoke no immune response or rejection after implantation. They then encapsulated the stem cells in the hydrogel, and in a process that mimics the embryonic development of the spinal cord, turned the cells into 3D implants of neuronal networks containing motor neurons.

 

Neural net (Photo: Sagol Center for Regenerative Biotechnology)

The human spinal cord implants were then implanted in two different groups of lab models: those who had only recently been paralyzed (the acute model) and those who had been paralyzed for a long time (the chronic model) – equivalent to one year in human terms. Following the implantation, 100% of the lab models with acute paralysis and 80% of those with chronic paralysis regained their ability to walk.

The groundbreaking study was led by Prof. Tal Dvir’s research team at the Sagol Center for Regenerative Biotechnology, The Shmunis School of Biomedicine and Cancer Research, and the Department of Biomedical Engineering at Tel Aviv University. The team at Prof. Dvir’s lab includes PhD student Lior Wertheim, Dr. Reuven Edri, and Dr. Yona Goldshmit.  Other contributors included Prof. Irit Gat-Viks from the Shmunis School of Biomedicine and Cancer Research, Prof. Yaniv Assaf from the Sagol School of Neuroscience, and Dr. Angela Ruban from The Stanley Steyer School of Health Professions at the Sackler Faculty of Medicine, all at Tel Aviv University. The results of the study were published in the prestigious scientific journal Advanced Science.

Visualization of the next stage of the research – human spinal cord implants for treating paralysis (Photo: Sagol Center for Regenerative Biotechnology)

Getting Patients Suffering from Paralysis Back on Their Feet

Encouragingly, the model animals underwent a rapid rehabilitation process, at the end of which they could walk quite well. This is the first instance in the world in which implanted engineered human tissues have generated recovery in an animal model for long-term chronic paralysis – which is the most relevant model for paralysis treatments in humans.

“Our goal is to produce personalized spinal cord implants for every paralyzed person, enabling regeneration of the damaged tissue with no risk of rejection,” says Prof. Dvir.

Based on the revolutionary organ engineering technology developed at Prof. Dvir’s lab, he teamed up with industry partners to establish Matricelf (matricelf.com) in 2019. The company applies Prof. Dvir’s approach in the aims of making spinal cord implant treatments commercially available for persons suffering from paralysis.

Prof. Dvir, head of Sagol Center for Regenerative Biotechnology, concludes: “We hope to reach the stage of clinical trials in humans within the next few years, and ultimately get these patients back on their feet. The company’s preclinical program has already been discussed with the FDA. Since we are proposing an advanced technology in regenerative medicine, and since at present there is no alternative for paralyzed patients, we have good reason to expect relatively rapid approval of our technology.” 

 

The research team (from left to right): Dr. Yona Goldshmit, Prof. Tal Dvir and Lior Wertheim  (Photo: Sagol Center for Regenerative Biotechnology)

 

Related posts

Want to Live Longer? Find Out if You Snore

May 15, 2022

TAU Researchers Invent Healthy Weapon Against Covid

April 14, 2022

Is the Vaccine Safe? Consult the Smart Sensor!

April 11, 2022

TAU Nanodrug Enables 2-in-1 Attack on Cancer

April 5, 2022

Minor Head Injury Leads to Chronic Post-Concussion Syndrome in 1 of 4 Children

March 28, 2022

Inventive Study to Develop Biological Solutions for Agriculture

March 27, 2022

TAU Technology Could Prevent Repeat Heart Valve Surgery

March 24, 2022

Israeli Breakthrough in Treating PTSD

February 22, 2022

Can Higher Temperatures Accelerate the Rate of Evolution?

February 16, 2022

Discovery May Enable Early Diagnosis of Alzheimer’s

February 15, 2022

Ketogenic Diet Likely to Reduce Damage from Traumatic Brain Injuries

January 25, 2022

Reading Tea Leaves

January 25, 2022

Viruses and Game Theory

January 24, 2022

What’s The Link Between Electrical Voltage and Brain Adaptability?

January 23, 2022

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

December 30, 2021

Rising Temperatures Fuel Increase in Violence: TAU Study

December 26, 2021

Medicinal Cannabis Oil Effective for Treating Autism

December 22, 2021

Parent Smartphone Use Could Harm Child Development

December 19, 2021

Breakthrough TAU Discovery Key to Reversing ALS

December 16, 2021

Experimental Drug Displays Effectiveness in Treating Symptoms of Autism and Alzheimer’s Disease

December 15, 2021

Seaweed – A Promising Defense Against Covid-19

December 15, 2021

New Ethical Code for World Research of Ancient DNA

December 14, 2021

Saving Lives with Artificial Intelligence

December 9, 2021

TAU Experts on Omicron: “Don’t Panic”

December 7, 2021

Tired of The Lies?

November 23, 2021

Britain and Israel Team Up on Challenge of Healthy Ageing

November 10, 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

November 8, 2021

Can’t Multitask Anymore?

October 6, 2021

Why Do We Squabble Over The AC?

October 5, 2021

The Immune System’s Double Agents

October 5, 2021

Help A Friend Out?

September 30, 2021

Using ‘Good’ Bacteria to Fight ‘Bad’ Bacteria

September 29, 2021

Recruiting ‘Fighting Cells’ to Destroy Tumors

September 14, 2021

TAU Team Reverses Early Signs of Alzheimer’s

September 10, 2021

Nicotine Testing of Children Curbs Parents’ Smoking

September 5, 2021

Want to Fall in Love? Step Outside in The Sun

August 31, 2021

The Silent Prophets

August 31, 2021

First 3D-bioprinting of entire active tumor

August 18, 2021

New Warning Sign for Breast Cancer

August 6, 2021

COVID-19 Immunity Varies Among Genders and Age Groups

July 26, 2021

Tel Aviv Bats Have More Fun

July 22, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

A world first: Technology that restores the sense of touch in nerves damaged as a result of amputation or injury

July 15, 2021

TAU Medical Student to Swim for Israel at Summer Olympics

July 15, 2021

New nanotech from TAU produces “healthy” electric current from the human body itself

July 9, 2021

Introducing the world’s thinnest technology – only two atoms thick

July 2, 2021

Want to Live a Long Life? Consider Investing in Your Marriage.

July 2, 2021

A world first: Targeted delivery of therapeutic RNAs only to cancer cells, with no harm caused to healthy cells

June 30, 2021

Combating Antibiotic Resistance

June 22, 2021

Diamonds in the Rough

June 3, 2021

Pursuing the Unknown

Copyright ©  Tel Aviv University Trust. All rights reserved.
Registered charity number 314179.